Journal
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
Volume 83, Issue -, Pages 417-428Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neubiorev.2017.10.028
Keywords
Cancer-related cognitive dysfunction; Neurocognitive impairment; Cancer survivorship; Quality of life; Breast cancer; Chemotherapy; Meta-analysis
Categories
Funding
- Princess Margaret Cancer Foundation
- Canadian Breast Cancer Foundation
- Canadian Institutes of Health Research disease management grant [RN 142313-261573]
Ask authors/readers for more resources
Women with breast cancer can experience persisting cognitive deficits post treatment. We conducted a multilevel meta-analysis of cognitive function in survivors treated with chemotherapy (Ch +) to estimate the magnitude of cognitive impairment relative to healthy (HC) and chemo-negative (Ch-) controls. Seventy-two studies published up to October 2016 involving 2939 Ch + yielded 1594 effect sizes. Ch + demonstrated overall cognitive impairment in comparison with HC but not with Ch-. Relative to HC, Ch + showed impairment in attention/concentration, processing speed, language, immediate recall, delayed recall, and executive function. Deficits in memory recall and executive function remained significant after adjusting for prechemotherapy group differences. Ch + performed worse than Ch- in attention/concentration and executive function, and the groups performed equivalently after accounting for prechemotherapy neurocognitive difference's. These results demonstrate that cognitive deficits in Ch + depend in large part on the comparison group, the cognitive domains examined, and whether prechemotherapy baseline neurocognition is measured. Cancer and/or other treatment related factors contribute to subtle memory recall and executive function impairments in breast cancer survivors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available